Please assess the completion status of the following clinical trial:

Trial Title: A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent.~* Male and female subjects 18 to 65 years of age with hepatitis C infections (genotypes 1, 2 or 3).~* No prior therapy or inadequate response to therapy for hepatitis C.~* Weight at least 50 kg and body mass index (BMI) within 18 - 35 kg/m2.~Exclusion Criteria:~* Use of other investigational drugs within at least 30 days of enrollment~* Women of child-bearing potential.~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LCQ908 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).